TEMPEST THERAPEUTICS INC. - COMMON STOCK

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

06 1 2025 08:00:00 提供 Nasdaq GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

06 12 2024 16:30:00 提供 Nasdaq GlobeNewswire

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

25 11 2024 16:30:00 提供 Nasdaq GlobeNewswire

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

12 11 2024 16:21:02 提供 Nasdaq GlobeNewswire

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

12 11 2024 08:00:02 提供 Nasdaq GlobeNewswire

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

10 10 2024 07:01:00 提供 Nasdaq GlobeNewswire

Tempest Extends Limited Duration Stockholder Rights Plan

10 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

20 9 2024 16:30:00 提供 Nasdaq GlobeNewswire

Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

18 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

23 8 2024 16:30:00 提供 Nasdaq GlobeNewswire

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

21 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

15 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

08 8 2024 16:56:29 提供 Nasdaq GlobeNewswire

Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

20 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

18 6 2024 18:22:51 提供 Nasdaq GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07 6 2024 04:30:00 提供 Nasdaq GlobeNewswire

Tempest to Participate in Upcoming Investor Conferences

21 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

09 5 2024 16:29:27 提供 Nasdaq GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

26 4 2024 16:05:17 提供 Nasdaq GlobeNewswire